Heparin Interactions

Heparin should not be included in the same syringe as Sotradecol due to incompatibility.

Source: NLP:(sotradecol) sodium tetradecyl sulfate

DEFITELIO may enhance the pharmacodynamic activity of heparin, increasing risk of hemorrhage. Concomitant use is contraindicated.

Source: NLP:defibrotide sodium

Heparin should not be included in the same syringe as Sotradecol due to incompatibility.

Source: NLP:sodium tetradecyl sulfate

Anticoagulant that increases bleeding risk when coadministered with apixaban.

Source: NLP:apixaban

Aspirin increases the anticoagulant activity of heparin, increasing bleeding risk.

Source: NLP:aspirin and dipyridamole

Aspirin increases the anticoagulant activity of heparin, increasing bleeding risk.

Source: NLP:aspirin and extended-release dipyridamole

Co-administration with bivalirudin associated with increased risk of major bleeding events in patients undergoing PCI/PTCA.

Source: NLP:bivalirudin

Concomitant use may increase the risk of bleeding. Avoid concomitant use when possible and monitor closely for bleeding.

Source: NLP:caplacizumab

Coadministration increases the risk of bleeding.

Source: NLP:eptifibatide

Possibility of increased bleeding due to pyridoxine interaction with anticoagulants.

Source: NLP:ferrous fumarate, folic acid

Heparin products containing sodium bisulfite reduce the absorption peak of Indocyanine Green in blood and should not be used as an anticoagulant for sample collection.

Source: NLP:indocyanine green and water

Administration should be done extremely cautiously with close monitoring due to potential increased bleeding risk, although in vitro studies showed minimal effect on template bleeding time.

Source: NLP:ketorolac tromethamine

Intravenous nitroglycerin interferes with the anticoagulant effect of heparin in some patients. Concomitant heparin therapy should be guided by frequent measurement of activated partial thromboplastin time.

Source: NLP:nitroglycerin

May increase potassium levels and lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Source: NLP:olmesartan medoxomil

Concurrent use of heparin with paroxetine may potentiate the risk of bleeding.

Source: NLP:paroxetine

Increased risk of bleeding with concurrent anticoagulant use; inform patients of increased bleeding risk.

Source: NLP:paroxetine hydrochloride hemihydrate

Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients.

Source: NLP:salicylic acid 10%

Concurrent use may potentiate bleeding risk. Inform patients of increased bleeding risk.

Source: NLP:sertraline

Concurrent use may potentiate risk of bleeding.

Source: NLP:sertraline hydrochloride

Heparin can increase serum potassium; concomitant use with spironolactone may lead to severe hyperkalemia.

Source: NLP:spironolactone

Concomitant administration may lead to severe hyperkalemia.

Source: NLP:spironolactone and hydrochlorothiazide

May increase serum potassium levels when used concomitantly with valsartan, potentially leading to increased serum creatinine in heart failure patients.

Source: NLP:valsartan and hydrochlorothiazide

Concomitant administration with alprostadil causes significant increases in partial thromboplastin time (140%) and thrombin time (120%). Caution should be exercised.

Source: NLP:alprostadil

May increase serum potassium levels when combined with valsartan. Monitor serum potassium levels.

Source: NLP:amlodipine and valsartan

Allow sufficient time for heparin's effect on aPTT to decrease before initiating argatroban therapy to avoid excessive anticoagulation.

Source: NLP:argatroban

May alter serum T4 and T3 transport affecting levothyroxine efficacy.

Source: NLP:levothyroxine sodium

May cause protein binding site displacement of thyroid hormones. Closely monitor thyroid hormone parameters.

Source: NLP:liothyronine sodium

Concurrent use of anticoagulants with paroxetine may potentiate the risk of bleeding.

Source: NLP:paroxetine hydrochloride

Monitor coagulation parameters in patients receiving piperacillin and tazobactam with heparin.

Source: NLP:piperacillin sodium and tazobactam sodium

May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.

Source: NLP:potassium bicarbonate

May increase potassium levels leading to increases in serum potassium and in heart failure patients, increases in serum creatinine. Monitoring is advisable.

Source: NLP:valsartan